Literature DB >> 26700117

Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?

Stephen R D Johnston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26700117     DOI： 10.1200/JCO.2015.64.0771

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Sukesh Voruganti; Rajesh Agarwal; Ruiwen Zhang
Journal:  Oncotarget       Date:  2016-05-31

2.  Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.

Authors:  Tengfei Xiao; Wei Li; Xiaoqing Wang; Han Xu; Jixin Yang; Qiu Wu; Ying Huang; Joseph Geradts; Peng Jiang; Teng Fei; David Chi; Chongzhi Zang; Qi Liao; Jonathan Rennhack; Eran Andrechek; Nanlin Li; Simone Detre; Mitchell Dowsett; Rinath M Jeselsohn; X Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

3.  Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Karen A Gelmon; Massimo Cristofanilli; Hope S Rugo; Angela M DeMichele; Anil A Joy; Aurelio Castrellon; Bethany Sleckman; Ave Mori; Kathy Puyana Theall; Dongrui R Lu; Xin Huang; Eustratios Bananis; Richard S Finn; Dennis J Slamon
Journal:  Breast J       Date:  2019-08-25       Impact factor: 2.431
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.